Han Lim

Han Lim is the Chief Business Officer of DeepCure, a Boston-based company building an end-to-end automated platform for small molecule drug discovery that pairs AI with a virtual library of a quintillion synthesizable compounds, robotic synthesis, and automated assays. A physician-scientist by training, he holds a medical degree from the University of Queensland, a PhD from the University of Cambridge, and did postdoctoral physics research at MIT before spending roughly a decade on the UC Berkeley faculty running a lab in systems biology and bioengineering. He helped build the first generation of AI drug discovery companies as Chief Business Officer at Atomwise, where he launched the internal pipeline, raised $168M across two rounds, and signed partners including Eli Lilly and Charles River Laboratories. He now leads business development, portfolio planning, and corporate strategy at DeepCure.